Levoxel

Levofloxacin hemihydrate

Community-acquired pneumonia, acute bacterial sinusitis, acute bacterial exacerbation of chronic bronchitis, skin & skin structure infections, complicated UTI, acute pyelonephritis.

500 mg by slow IV infusion over 60 min every 24 hr. Adult Community-acquired pneumonia 500 mg once daily for 7-14 days or 750 mg once daily for 5 days. Uncomplicated skin & skin structure infection (SSSI) 500 mg once daily for 7-10 days. Complicated SSSI 750 mg once daily for 7-14 days. Complicated UTI (cUTI) or acute pyelonephritis (AP) 250 mg once daily for 10 days or 750 mg once daily for 5 days. Renal impairment CrCl 20-49 mL/min 750 mg every 48 hr or, 500 mg initially then 250 mg every 24 hr; 10-19 mL/min 750 mg initially then 500 mg every 48 hr or, 500 mg initially then 250 mg every 48 hr or, 250 mg every 48 hr. Hemodialysis or chronic ambulatory peritoneal dialysis (CAPD) 750 mg initially then 500 mg every 48 hr or; 500 mg initially then 250 mg every 48 hr.

Hypersensitivity to levofloxacin or other quinolones.

Discontinue immediately at the 1st appearance of skin rash, jaundice or any other sign of hypersensitivity; if signs & symptoms of hepatitis develops; if patient experiences symptoms of neuropathy. Increased risk of tendinitis & tendon rupture especially in elderly over 60 yr, those taking corticosteroids, & in patients w/ kidney, heart or lung transplants. Known or suspected CNS disorders (eg, severe cerebral arteriosclerosis, epilepsy) or in the presence of other risk factors (eg, certain drug therapy, renal dysfunction) that may predispose to seizures or lower the seizure threshold. Clostridium difficile-associated diarrhea. Avoid in patients w/ known history of myasthenia gravis; prolongation of QT interval, uncorrected hypokalemia, & those receiving class IA (quinidine, procainamide) or class III (amiodarone, sotalol) antiarrhythmic agents. Indicated only for the prevention of inhalational anthrax (post exposure) in ped patients ≥6 mth. Moderate to severe photosensitivity/phototoxicity reactions after sun or UV light exposure. Risk of developing drug-resistant bacteria. Concomitant use w/ oral hypoglycemic agent (eg, glyburide) or w/ insulin. Pregnancy & lactation. Childn (increased incidence of musculoskeletal disorders).

Upset stomach, nausea, diarrhea, headache, dizziness, lightheadedness, trouble sleeping. Sun sensitivity, tremor, mental/mood changes.

Enhanced effects of warfarin. Blood glucose disturbances, including hyperglycemia & hypoglycemia w/ antidiabetic agents. May increase risk of CNS stimulation & convulsive seizures w/ NSAIDs. Prolonged elimination t_1/2, elevated serum levels, & subsequent increase in risk of theophylline-related adverse reactions. Elevated serum levels of cyclosporine. Do not co-administer in the same IV line w/ any soln containing multivalent cations eg, Mg. May produce false +ve urine screening results for opiates.

Quinolones

J01MA12 - levofloxacin ; Belongs to the class of fluoroquinolones. Used in the systemic treatment of infections.

Rx